Early trial data shows that a combination of Mirati Therapeutics experimental drug adagrasib and Merck & Co.’s immunotherapy Keytruda helped about half of previously untreated metastatic lung cancer patients, with manageable side effects, Mirati said on Monday.
With Novartis facing a potential loss of $9 billion through 2026 from patent expirations, the company announced topline results for Pluvicto for PSMA-positive metastatic castration-resistant prostate cancer (mCRPC).
Jazz Pharmaceuticals plc announced new real-world data from the BECOME (BEhavior, COgnition, and More with Epidiolex) Caregiver Survey that showed a substantial proportion of caregivers of adult and pediatric patients with Lennox-Gastaut Syndrome (LGS) and Dravet Syndrome (DS) prescribed Epidiolex (cannabidiol) oral solution reported improvements in patients’ seizure and non-seizure outcomes across all age groups.
Ionis Pharmaceuticals Inc. announced that the European Medicines Agency (EMA) has accepted the marketing authorization application (MAA) for review of tofersen, an investigational medicine for the treatment of superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS). SOD1-ALS is a progressive and uniformly fatal disease that affects fewer than 1,000 people across Europe.
Amgen Inc.’s experimental obesity drug demonstrated promising durability trends in an early trial, paving the way for a larger mid-stage study early next year, company officials said ahead of a data presentation on Saturday.
GSK plans to file for approval of Jemperli in endometrial cancer after the checkpoint inhibitor met its primary endpoint in the Phase III RUBY trial, the company announced Friday.
Athira Pharma’s experimental Alzheimer’s therapy, fosgonimeton, continues to show signs of being able to improve cognition and function in patients.
While acquiring Horizon would add a mixed portfolio of specialty drugs to Sanofi’s roster, it would not address the French company’s need to develop its drug pipeline and improve its productivity from research and development, analysts say.
PictorLabs emerged from stealth mode Thursday with $15 million to advance its AI-powered virtual staining platform that researchers hope will “reimagine the future” of histopathology.
Nimbus Therapeutics reported positive Phase IIb results on Wednesday for its TYK2 inhibitor, NDI-034858, in moderate-to-severe plaque psoriasis.
